70 related articles for article (PubMed ID: 27382749)
1. [Cytological Study in vitro on Co-delivery of siRNA and Paclitaxel within Solid Lipid Nanoparticles to Overcome Multidrug Resistance in Tumors].
Huang R; Yao X; Chen Y; Sun X; Lin Y
Sheng Wu Yi Xue Gong Cheng Xue Za Zhi; 2016 Feb; 33(1):108-14. PubMed ID: 27382749
[TBL] [Abstract][Full Text] [Related]
2. Combating multidrug resistance of breast cancer with ginsenoside Rh2-irrigated nano-in-thermogel.
Long J; Hu W; Ren T; Wang X; Lu C; Pan X; Wu C; Peng T
Int J Pharm; 2024 Jan; 650():123718. PubMed ID: 38104849
[TBL] [Abstract][Full Text] [Related]
3. Co-delivery of Paclitaxel/Atovaquone/Quercetin to regulate energy metabolism to reverse multidrug resistance in ovarian cancer by PLGA-PEG nanoparticles.
Lu Q; Gao W; Chen Z; Liu Z; Wang J; Zeng L; Hu X; Zheng E; Zhang Q; Song H
Int J Pharm; 2024 Apr; 655():124028. PubMed ID: 38518871
[TBL] [Abstract][Full Text] [Related]
4. Multifunctional nanoparticles delivering small interfering RNA and doxorubicin overcome drug resistance in cancer.
Chen Y; Bathula SR; Li J; Huang L
J Biol Chem; 2010 Jul; 285(29):22639-50. PubMed ID: 20460382
[TBL] [Abstract][Full Text] [Related]
5. pH-triggered surface charge-switchable polymer micelles for the co-delivery of paclitaxel/disulfiram and overcoming multidrug resistance in cancer.
Huo Q; Zhu J; Niu Y; Shi H; Gong Y; Li Y; Song H; Liu Y
Int J Nanomedicine; 2017; 12():8631-8647. PubMed ID: 29270012
[TBL] [Abstract][Full Text] [Related]
6. A simple reduction-sensitive micelles co-delivery of paclitaxel and dasatinib to overcome tumor multidrug resistance.
Li J; Xu R; Lu X; He J; Jin S
Int J Nanomedicine; 2017; 12():8043-8056. PubMed ID: 29138561
[TBL] [Abstract][Full Text] [Related]
7. A convenient protonated strategy for constructing nanodrugs from hydrophobic drug-inhibitor conjugates to reverse tumor multidrug resistance.
Wang P; Wang Y; Xia X; Wu J; Lin J; Huang W; Yan D
Nanoscale; 2024 May; 16(17):8434-8446. PubMed ID: 38592819
[TBL] [Abstract][Full Text] [Related]
8. Combinatorial therapeutic approaches with RNAi and anticancer drugs using nanodrug delivery systems.
Babu A; Munshi A; Ramesh R
Drug Dev Ind Pharm; 2017 Sep; 43(9):1391-1401. PubMed ID: 28523942
[TBL] [Abstract][Full Text] [Related]
9. Enhancing Paclitaxel Efficacy with Piperine-Paclitaxel Albumin Nanoparticles in Multidrug-Resistant Triple-Negative Breast Cancer by Inhibiting P-Glycoprotein.
Xu W; Xiao Y; Zheng L; Xu M; Jiang X; Wang L
Pharmaceutics; 2023 Nov; 15(12):. PubMed ID: 38140044
[TBL] [Abstract][Full Text] [Related]
10. The critical size of gold nanoparticles for overcoming P-gp mediated multidrug resistance.
Jiang Y; Wang Z; Duan W; Liu L; Si M; Chen X; Fang CJ
Nanoscale; 2020 Aug; 12(31):16451-16461. PubMed ID: 32790812
[TBL] [Abstract][Full Text] [Related]
11. P-glycoprotein antibody-conjugated paclitaxel liposomes targeted for multidrug-resistant lung cancer.
Wang J; Suo X; Zhang H
Nanomedicine (Lond); 2023 Apr; 18(10):819-831. PubMed ID: 37306214
[No Abstract] [Full Text] [Related]
12. PD-L1 monoclonal antibody-decorated nanoliposomes loaded with Paclitaxel and P-gp transport inhibitor for the synergistic chemotherapy against multidrug resistant gastric cancers.
Yu J; Hu F; Zhu Q; Li X; Ren H; Fan S; Qian B; Zhai B; Yang D
Nanoscale Res Lett; 2020 Mar; 15(1):59. PubMed ID: 32166458
[TBL] [Abstract][Full Text] [Related]
13. Targeted Dual pH-Sensitive Lipid ECO/siRNA Self-Assembly Nanoparticles Facilitate In Vivo Cytosolic sieIF4E Delivery and Overcome Paclitaxel Resistance in Breast Cancer Therapy.
Gujrati M; Vaidya AM; Mack M; Snyder D; Malamas A; Lu ZR
Adv Healthc Mater; 2016 Nov; 5(22):2882-2895. PubMed ID: 27723260
[TBL] [Abstract][Full Text] [Related]
14. Simultaneous delivery of Paclitaxel and Bcl-2 siRNA via pH-Sensitive liposomal nanocarrier for the synergistic treatment of melanoma.
Reddy TL; Garikapati KR; Reddy SG; Reddy BV; Yadav JS; Bhadra U; Bhadra MP
Sci Rep; 2016 Oct; 6():35223. PubMed ID: 27786239
[TBL] [Abstract][Full Text] [Related]
15. Self-Assembled nanoparticles of natural bioactive molecules enhance the delivery and efficacy of paclitaxel in glioblastoma.
Li Y; Zhao Q; Zhu X; Zhou L; Song P; Liu B; Tian D; Chen Q; Zhou J; Deng G
CNS Neurosci Ther; 2024 Apr; 30(4):e14528. PubMed ID: 38044793
[TBL] [Abstract][Full Text] [Related]
16. Phospholipid-modified PEI-based nanocarriers for in vivo siRNA therapeutics against multidrug-resistant tumors.
Essex S; Navarro G; Sabhachandani P; Chordia A; Trivedi M; Movassaghian S; Torchilin VP
Gene Ther; 2015 Mar; 22(3):257-266. PubMed ID: 25354685
[TBL] [Abstract][Full Text] [Related]
17. Preparation and evaluation of cytotoxic potential of paclitaxel containing poly-3-hydroxybutyrate-co-3-hydroxyvalarate (PTX/PHBV) nanoparticles.
Aslam A; Berger MR; Ullah I; Hameed A; Masood F
Braz J Biol; 2023; 83():e275688. PubMed ID: 37970904
[TBL] [Abstract][Full Text] [Related]
18. Multimodal Nanoplatform with ROS Amplification to Overcome Multidrug Resistance in Prostate Cancer via Targeting P-Glycoprotein and Ferroptosis.
Guan Y; Lei H; Xing C; Yan B; Lin B; Yang X; Huang H; Kang Y; Pang J
Adv Healthc Mater; 2024 Jan; 13(3):e2301345. PubMed ID: 37855250
[TBL] [Abstract][Full Text] [Related]
19. Effective therapy of advanced breast cancer through synergistic anticancer by paclitaxel and P-glycoprotein inhibitor.
Zhu S; Sun C; Cai Z; Li Y; Liu W; Luan Y; Wang C
Mater Today Bio; 2024 Jun; 26():101029. PubMed ID: 38545262
[TBL] [Abstract][Full Text] [Related]
20. A ciprofloxacin derivative with four mechanisms of action overcomes paclitaxel resistance in p53-mutant and MDR1 gene-expressing type II human endometrial cancer.
Alhaj-Suliman SO; Naguib YW; Wafa EI; Saha S; Ebeid K; Meng X; Mohammed HH; Abuo-Rahma GEA; Yang S; Salem AK
Biomaterials; 2023 May; 296():122093. PubMed ID: 36965280
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
